{"disease":{"id":"second-line-treatment","name":"second line treatment"},"drugs":{"marketed":[{"drug_id":"anastrozole","indication_name":"Second-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"chembl-chembl1444","indication_name":"Second-line treatment of advanced breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Second-Line Treatment of Advanced Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"folfiri","indication_name":"Second-line treatment of metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT07389876","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06662877","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":206,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06814548","title":"Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Yongxu Jia","has_results":false},{"nct_id":"NCT06666582","title":"Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06374160","title":"Exercise in Patients With Advanced Non-small Cell Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT06518018","title":"Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"The First People's Hospital of Neijiang","has_results":false},{"nct_id":"NCT07138885","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04522908","title":"Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT06446154","title":"Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03251443","title":"A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06992024","title":"Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04193098","title":"Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}